{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Renal+Pelvis+Carcinoma&page=4", "query": { "condition": "Renal Pelvis Carcinoma", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 112, "total_pages": 12, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Renal+Pelvis+Carcinoma&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Renal+Pelvis+Carcinoma&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-17T23:11:30.058Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04724018", "title": "Sacituzumab Govitecan Plus EV in Metastatic UC", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Urothelial Cancer", "Metastatic Urothelial Carcinoma", "Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter", "Bladder Cancer" ], "interventions": [ { "name": "Sacituzumab Govitecan (SG)", "type": "DRUG" }, { "name": "Enfortumab vedotin-ejfv (EV)", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 106, "start_date": "2021-05-20", "completion_date": "2028-05-01", "has_results": false, "last_update_posted_date": "2025-11-04", "last_synced_at": "2026-10-17T23:11:30.058Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04724018" }, { "nct_id": "NCT04398368", "title": "Gemcitabine for the Prevention of Intravesical Recurrence of Urothelial Cancer in Patients With Upper Urinary Tract Urothelial Cancer Undergoing Radical Nephroureterectomy, GEMINI Study", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stage 0a Renal Pelvis and Ureter Cancer AJCC v8", "Stage 0a Renal Pelvis Cancer AJCC v8", "Stage 0a Ureter Cancer AJCC v8", "Stage 0is Renal Pelvis and Ureter Cancer AJCC v8", "Stage 0is Renal Pelvis Cancer AJCC v8", "Stage 0is Ureter Cancer AJCC v8", "Stage I Renal Pelvis and Ureter Cancer AJCC v8", "Stage I Renal Pelvis Cancer AJCC v8", "Stage I Ureter Cancer AJCC v8", "Stage II Renal Pelvis and Ureter Cancer AJCC v8", "Stage II Renal Pelvis Cancer AJCC v8", "Stage II Ureter Cancer AJCC v8", "Stage III Renal Pelvis and Ureter Cancer AJCC v8", "Stage III Renal Pelvis Cancer AJCC v8", "Stage III Ureter Cancer AJCC v8", "Stage IV Renal Pelvis and Ureter Cancer AJCC v8", "Stage IV Renal Pelvis Cancer AJCC v8", "Stage IV Ureter Cancer AJCC v8" ], "interventions": [ { "name": "Gemcitabine Hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2020-06-05", "completion_date": "2023-02-02", "has_results": true, "last_update_posted_date": "2023-08-08", "last_synced_at": "2026-10-17T23:11:30.058Z", "location_count": 4, "location_summary": "Jacksonville, Florida • Rochester, Minnesota • Winston-Salem, North Carolina + 1 more", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Winston-Salem", "state": "North Carolina" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04398368" }, { "nct_id": "NCT05756569", "title": "Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bladder Squamous Cell Carcinoma", "Locally Advanced Bladder Carcinoma", "Malignant Renal Pelvis Neoplasm", "Malignant Ureter Neoplasm", "Malignant Urethral Neoplasm", "Metastatic Bladder Carcinoma", "Stage III Bladder Cancer AJCC v8", "Stage IV Bladder Cancer AJCC v8", "Unresectable Bladder Carcinoma", "Urachal Adenocarcinoma", "Bladder Adenocarcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Enfortumab Vedotin", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2023-09-26", "completion_date": "2027-12-16", "has_results": false, "last_update_posted_date": "2026-07-29", "last_synced_at": "2026-10-17T23:11:30.058Z", "location_count": 4, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05756569" }, { "nct_id": "NCT06661720", "title": "Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Clear Cell Renal Cell Carcinoma", "Renal Cell Carcinoma (RCC)", "Stage II Renal Pelvis Cancer AJCC v8", "Stage III Renal Pelvis Cancer AJCC v8" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Tivozanib", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "MRI", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "OTHER" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1040, "start_date": "2025-03-14", "completion_date": "2037-11", "has_results": false, "last_update_posted_date": "2026-09-02", "last_synced_at": "2026-10-17T23:11:30.058Z", "location_count": 425, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 339 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06661720" }, { "nct_id": "NCT00009867", "title": "Arsenic Trioxide in Treating Patients With Urothelial Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter", "Recurrent Urethral Cancer", "Transitional Cell Carcinoma of the Bladder", "Ureter Cancer" ], "interventions": [ { "name": "arsenic trioxide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2000-12", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-06-04", "last_synced_at": "2026-10-17T23:11:30.058Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00009867" }, { "nct_id": "NCT04628767", "title": "Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Renal Pelvis and Ureter Urothelial Carcinoma" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Gemcitabine Hydrochloride", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Pegfilgrastim", "type": "BIOLOGICAL" }, { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" }, { "name": "Vinblastine Sulfate", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 131, "start_date": "2021-11-12", "completion_date": "2027-09-30", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-17T23:11:30.058Z", "location_count": 257, "location_summary": "Kingman, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 197 more", "locations": [ { "city": "Kingman", "state": "Arizona" }, { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Auburn", "state": "California" }, { "city": "Berkeley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04628767" }, { "nct_id": "NCT01234519", "title": "A Phase I/II Trial of AEZS-108 in Urothelial Cancer Patients Who Failed Platinum-chemotherapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Urothelial Carcinoma" ], "interventions": [ { "name": "AEZS-108", "type": "DRUG" }, { "name": "AEZS-108 at MTD", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AEterna Zentaris", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2010-11", "completion_date": "2014-11", "has_results": false, "last_update_posted_date": "2018-03-15", "last_synced_at": "2026-10-17T23:11:30.058Z", "location_count": 2, "location_summary": "Miami, Florida • Philadelphia, Pennsylvania", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01234519" }, { "nct_id": "NCT02426125", "title": "A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Urothelial Carcinoma" ], "interventions": [ { "name": "Ramucirumab", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 530, "start_date": "2015-07-13", "completion_date": "2022-07-26", "has_results": true, "last_update_posted_date": "2023-08-21", "last_synced_at": "2026-10-17T23:11:30.058Z", "location_count": 33, "location_summary": "Fayetteville, Arkansas • Fullerton, California • Los Angeles, California + 28 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Fullerton", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02426125" }, { "nct_id": "NCT00020579", "title": "MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "entinostat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institutes of Health Clinical Center (CC)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 75, "start_date": "2001-03", "completion_date": "2008-10", "has_results": false, "last_update_posted_date": "2012-03-15", "last_synced_at": "2026-10-17T23:11:30.058Z", "location_count": 3, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00020579" }, { "nct_id": "NCT04115254", "title": "Stereotactic Magnetic Resonance Guided Radiation Therapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Pancreas Cancer", "Lung Cancer", "Renal Cancer", "Adrenal Metastases", "Prostate Cancer", "Liver Metastases", "Oligoprogressive Nodal Metastases", "Metachronous Nodal Metastases", "Synchronous Nodal Metastases", "Mesothelioma", "Spine Metastases", "Brain Metastases", "Borderline Resectable Pancreatic Carcinoma" ], "interventions": [ { "name": "MR-guided Linac", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 397, "start_date": "2019-10-22", "completion_date": "2028-06", "has_results": false, "last_update_posted_date": "2025-11-13", "last_synced_at": "2026-10-17T23:11:30.058Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04115254" } ] }